Page 53 - AN-4-4
P. 53

Advanced Neurology                                                  Lipid metabolism and Parkinson’s disease



               doi: 10.1007/s13238-014-0131-3                  142. Dai L, Wang J, Meng L, et al. The cholesterol 24-hydroxylase
                                                                  CYP46A1 promotes  α-synuclein pathology in Parkinson’s
            137. Guo J, Chen S, Zhang Y,  et al. Cholesterol metabolism:
               Physiological regulation and diseases.  MedComm (2020).   disease. PLoS Biol. 2025;23(2):e3002974.
               2024;5(2):e476.                                    doi: 10.1371/journal.pbio.3002974
               doi: 10.1002/mco2.476                           143. Dai L, Wang J, Zhang X, et al. 27-Hydroxycholesterol drives
            138.  Musanti R, Parati E, Lamperti E, Ghiselli G. Decreased cholesterol   the spread of α-synuclein pathology in Parkinson’s disease.
               biosynthesis in fibroblasts from patients with Parkinson disease.   Mov Disord. 2023;38(11):2005-2018.
               Biochem Med Metab Biol. 1993;49(2):133-142.        doi: 10.1002/mds.29577
               doi: 10.1006/bmmb.1993.1016                     144. Doria M, Maugest L, Moreau T, Lizard G, Vejux A.
            139. Reiss AB, Wirkowski E. Role of HMG-CoA reductase   Contribution of  cholesterol  and  oxysterols  to  the
               inhibitors in neurological disorders: Progress to date. Drugs.   pathophysiology of Parkinson’s disease. Free Radic Biol Med.
               2007;67(15):2111-2120.                             2016;101:393-400.
               doi: 10.2165/00003495-200767150-00001              doi: 10.1016/j.freeradbiomed.2016.10.008
            140. Al-kuraishy HM, Fahad EH, Al-Windy S, El-Sherbeni SA,   145. Falabella M, Vernon HJ, Hanna MG, Claypool SM, Pitceathly
               Negm WA, Batiha GE-S. The effects of cholesterol and   RDS. Cardiolipin, mitochondria, and neurological disease.
               statins on Parkinson’s neuropathology: A narrative review.   Trends Endocrinol Metab. 2021;32(4):224-237.
               Inflammopharmacology. 2024;32(2):917-925.          doi: 10.1016/j.tem.2021.01.006
               doi: 10.1007/s10787-023-01400-z                 146. Tong B, Ba Y, Li Z,  et al. Targeting dysregulated lipid
            141. Nakamura K, Mori F, Tanji K, et al. Isopentenyl diphosphate   metabolism for the treatment of Alzheimer’s disease and
               isomerase, a cholesterol synthesizing enzyme, is localized in   Parkinson’s disease: Current advancements and future
               Lewy bodies. Neuropathology. 2015;35(5):432-440.   prospects. Neurobiol Dis. 2024;196:106505.
               doi: 10.1111/neup.12204                            doi: 10.1016/j.nbd.2024.106505












































            Volume 4 Issue 4 (2025)                         47                           doi: 10.36922/AN025320086
   48   49   50   51   52   53   54   55   56   57   58